Currently, several monoclonal antibodies (e.g., amatuximab) and antibody–drug conjugates (e.g., anetumab ravtansine) targeting MSLN are being investigated in preclinical and clinical trials, particularly for mesothelioma [53,54] and ovarian cancer [55,56]. This evidence concerns the gene MSLN and ovarian carcinoma.